



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

21 Jun 2021 (#18)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

[NOT-AG-21-029](#) NIA Announces New Policy and Procedures for the Reporting of Human Subjects Enrollment Data for NIA Clinical Research Trials/Studies. The purpose of this Notice is to inform the research community of the National Institute on Aging (NIA) new policy and procedures for reporting enrollment data for clinical research trials/studies funded through an NIA funding mechanism (including grants, contracts, and cooperative agreements). This Notice details the new requirements, expectations of NIA-funded investigators, and impetus for the policy change.

[NOT-AG-21-027](#) Notice of Participation of the National Institute on Aging (NIA) in PAR-21-230 "Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)"

[NOT-AI-21-064](#) Notice of Intent to Publish a Funding Opportunity Announcement for Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern (U19 Clinical Trial Not Allowed). The National Institute of Allergy and Infectious Diseases (NIAID) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications to establish Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. This multidisciplinary research program will focus on advancing discovery and development of new or improved antivirals targeting coronaviruses, with an emphasis on SARS-CoV-2, and one or more viral pathogens from the following RNA virus families of pandemic potential: Paramyxoviruses; Bunyaviruses (Bunyavirales); Togaviruses; Filoviruses; Picornaviruses; or Flaviviruses. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The open FOA is expected to be published in mid-summer 2021. A pre-application informational webinar for prospective applicants is being planned. Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply. Estimated Total Funding \$200,000,000. NIAID anticipates funding up to 8 awards, contingent upon the availability of funds. NIAID intends to cap direct costs at \$15 million.

[NOT-AI-21-056](#) Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies. This Notice of Special Interest (NOSI) is to inform potential applicants of NIAID's interest in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. This is needed to improve the guidance available to treatment and prevention programs for both individuals and populations. Research responsive to this NOSI could include the development of: (i) highly sensitive mutation detection technologies that can be integrated into multiplex assay systems capable of simultaneous assessment of large numbers of potential mutations (ii) point of care (POC) DR assays, **or** (iii) strategies for rapid acquisition, curation and analysis of these HIV DR data and timely dissemination to healthcare providers and public health decision makers. Strategies applicable to [low and middle income countries as defined by the World Bank](#) are especially encouraged. This notice applies to due dates on or after **5 September 2021** and subsequent receipt dates through **7 May 2024**.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Role of Adaptive Immunity in Etiology of Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-22-017](#)

Type: R01

Application Due Date: October 28, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) aims to explore the role of adaptive immunity in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, the FOA seeks an understanding of brain immune surveillance, the generation of CNS-directed immune responses in neurodegenerative disorders, and the functional role of adaptive immunity in AD/ADRD onset and progression.

Budget: The National Institute on Aging intends to commit \$8 million in FY 2022 to fund 10-12 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AG-22-018](#)

Type: R01

Application Due Date: 28 October 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits secondary analyses of existing datasets to provide evidence about appropriate strategies for long-term osteoporosis therapies, including drug holidays, and to better understand their risks and benefits. This FOA encourages interdisciplinary studies utilizing innovative analytical approaches such as modeling studies or causal inference methods using data sources from large cohort studies, healthcare systems including the Veterans Administration (VA), Centers for Medicare and Medicaid Services (CMS), FDA Sentinel network, Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), and other public, private, or commercial datasets. The generalizability of study results is critical, and datasets should be representative of the population receiving osteoporosis therapy. Identification of disparities in outcomes according to demographic, ethnic, clinical, social, and other factors are particularly encouraged.

Budget: NIA intends to commit \$2,500,000 in FY 2022 to fund 2-3 awards. Application budgets are limited to \$750,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-009](#)

Type: R01

Application Due Date: 17 November 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines. Specific emphasis is on the comorbidity of HIV and neural stimulants, including methamphetamine, amphetamine, cocaine, and nicotine, studied at the single cell and neural circuits levels.

Budget: NIDA intends to commit \$2,000,000 in FY22 to fund 3 to 6 awards. Application budgets are limited to no more than \$500,000 per year in direct cost. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105